Optimal concentration range of ustekinumab in patients with plaque-type psoriasis - 16/05/19
![](/templates/common/images/mail.png)
Funding sources: Dr Martín-González is supported by a Zabalduz predoctoral grant from Universidad del Pais Vasco/Euskal Herriko Unibertsitatea, Spain. |
|
Disclosure: Dr Ruiz del Agua and Dr Nagore are full-time employees of Progenika Biopharma. Dr Izu-Belloso has conducted clinical trials or received honoraria for serving as a consultant for Pfizer Pharmaceuticals, AbbVie, Janssen-Cilag Pharmaceutical, Novartis Pharmaceuticals, Celgene, and Eli Lilly and Company. Dr Urigoitia-Ugalde has conducted clinical trials for Janssen-Cilag Pharmaceutical and Novartis Pharmaceuticals. Dr Blanch has conducted clinical trials for Novartis Pharmaceuticals. Dr Martín-González, Dr Careaga, Dr Navarro, and Dr González del Tánago have no conflicts of interest to disclose. |
|
Reprints not available from the authors. |
Vol 80 - N° 6
P. 1782-1784 - juin 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?